6.26.2008 - 09:48am ET

(CSRwire) - June 26, 2008 - Innovest Strategic Value Advisors invites you to join Senior Analyst Veronique Menou in the Innovest webinar "Access to Medicine: Growth Opportunities and Risk Exposure for the Drug Industry."

On Monday June 16th, Innovest launched the Access to Medicine Index a ranking of 20 pharmaceutical companies with regards to access to medicines. The ranking, as illustrated below, evaluates companies in the areas of Management, Influence, R&D, Patenting, Capacity, Pricing, Drug Donations, and Philanthropy.

Over the past few years, the drug industry has faced various challenges including more stringent regulations, weak product pipeline and increasing competition from generic companies demonstrating the limits of the blockbuster model.In response companies have looked at emerging markets for growth opportunities increasing their exposure to risks associated with access to medicines.


Why is this important for investors?
The AtM Index is the first attempt to turn research from academic, investors, governments, NGOs and companies into an evaluation of company performance. The AtM Index offers a deep analysis of pharmaceutical companies’ practices relating to ATMs using a precise set of quantitative and qualitative indicators. It also allows for a benchmark of companies' performance based on their business model and a better understanding of the management of risks and the creation of sustainable opportunities in emerging economies.

Innovest invites you to join Senior Analyst Veronique Menou at 10AM EST on 25 June 2008 in the Innovest webinar "Access to Medicine: Growth Opportunities and Risk Exposure for the Drug Industry." To register, click here.

Ratings and research reports from Innovest Strategic Advisors analyzing the environmental, social and governance performance of over 1,750 companies and their industries, including the Global 100 Most Sustainable Corporations, is available through Innovest's partner CSRwire at www.csrwire.com/reports/independent




About Innovest

Innovest Strategic Value Advisors is an internationally recognized investment research and advisory firm specializing in analyzing companies’ performance on environmental, social, and strategic governance issues, with a particular focus on their impact on competitiveness, profitability, and share price performance.

Innovest currently has offices in New York City, Toronto, San Francisco, London, Paris, Sydney, and Tokyo.

For more information please contact: